The Market is segmented by Management Devices (Insulin Pumps, Insulin Syringes, Insulin Disposable Pens, Insulin Cartridges in Reusable Pens, Insulin Jet Injectors) and Monitoring Devices (Self-monitoring Blood Glucose and Continuous Glucose Monitoring), and Geography.

Canada Diabetes Care Devices Industry Overview

Canada Diabetes Devices Market Summary
Study Period: 2018 - 2028
CAGR: > 6 %

Major Players

Canada Diabetes Devices Market Major Players

*Disclaimer: Major Players sorted in no particular order


Need a report that reflects how COVID-19 has impacted this market and its growth?

Canada Diabetes Care Devices Market Analysis

Canada Diabetes Care Devices Market is expected to register a CAGR greater than 6% over the forecast period, 2022-2027.

Canada has 107,861 cases of coronavirus disease 2019 (COVID-19) (286 per 1,00,000 individuals) and 8787 COVID-19-related fatalities as of July 13, 2020. In Canada, public health is overseen at the federal, provincial, and regional levels, and the Canadian constitution delegates healthcare authority to the country's ten provinces and three territories. As a result, similar to the United States, where individual states generally defined the COVID-19 response, Canadian provinces have mostly selected containment and mitigation plans. Provincial public health authorities collaborated closely with regional public health officers and municipal governments to develop policies and recommendations, as well as to put services like testing and contact tracing in place. Blood pressure regulation is a critical component of diabetes management. Furthermore, even in the absence of high blood pressure, certain blood pressure lowering medications are frequently recommended for people living with diabetes to protect them from kidney and heart-related complications. There is currently no scientific evidence linking these blood pressure drugs to the likelihood of COVID-19 infection or associated consequences.

In Canada, During the pandemic, many healthcare providers have adopted a hybrid model of care, offering certain types of visits in-person at the clinic and others virtually, by phone, video chat, or secure messaging. Virtual diabetes care may be a new and different experience for you. For tips on preparing for your diabetes visit and managing virtual appointments.

Canada Diabetes Care Devices Industry Segments

Canada Diabetes Care Devices Market is expected to register a CAGR greater than 6% over the forecast period, 2022-2027. The Canada Diabetes Care Devices Market is segmented by devices (Management Devices (Insulin Pumps, Insulin Pens, Syringes, Cartridges, and Jet Injectors) and Monitoring Devices (Self-monitoring Blood and Continuous Glucose Monitoring)).

By Device
By Monitoring Devices, (Value and Volume, 2016 - 2027)
Self-monitoring Blood Glucose Devices
Glucometer Devices
Test Strips
Continuous Glucose Monitoring
Receivers (Receivers and Transmitters)
By Management Devices, (Value and Volume, 2016 - 2027)
Insulin Delivery Devices
Insulin Pump
Insulin Pump Device
Insulin Pump Reservoir
Infusion Set
Insulin Syringes
Insulin Disposable Pens
Insulin Cartridges in Reusable pens
Insulin Jet Injectors

Report scope can be customized per your requirements. Click here.

Canada Diabetes Care Devices Market Trends

This section covers the major market trends shaping the Canada Diabetes Care Devices Market according to our research experts:

The Continuous Glucose Monitoring Devices Market Segment is Growing Fast with the highest CAGR Among Other Segments in Canada Diabetes Care Devices Market.

The Diabetes Canada Clinical Practice Guidelines review committee updated its recommendations for glucose monitoring in 2021, stating that individuals with type 1 diabetes treated with basal-bolus insulin injections or an insulin pump should use real-time CGM, such as the Dexcom G6, to reduce A1C and increase time in range, reduce duration and incidence of hypoglycemia, and, in adults, improve quality of life. 5 The guidelines also suggest that persons with type 2 diabetes who are not on target with basal-bolus insulin can utilize real-time CGM to lower A1C and duration of hypoglycemia.

Some private plans provide CGM coverage in Canada. However, public funding is only currently available for people who have access to the Ontario Disability Support Program or the Non-Insured Health Benefits program for First Nations and Inuit. All others must pay the entire cost out-of-pocket, and no other provinces or territories currently publicly fund this technology. CGM systems typically range in price from USD 3,000 to USD 6,000 a year. Many people cannot afford this cost. The cost can vary between manufacturers and is based on the components of the system and the frequency with which equipment needs to be replaced.

Through Canadian government encouragement, the usage of Continuous Glucose Monitoring Devices increased over the forecast period.

Canada Diabetes Care Devices Market: Revenue in USD million, cGM devices, (2022-2027)

Increasing diabetes Population in Canada driving the market.

According to the Canadian Diabetes Association (CDA), in 2021, around 11.5 million people in Canada were diagnosed with diabetes.

Diabetes Canada released new 2022 figures that show the continued rising trend of diabetes rates in Canada with no signs of leveling or decreasing. Diabetes continues to affect more Canadians than ever before and reasserts the need for further investment into diabetes research to help turn the tide. “The new diabetes figures show a steady, continued increase in diabetes in our country with 11.7 million Canadians living with diabetes or prediabetes,”.

In 2022, According to Canada Diabetes, more than 5.7 million Canadians are living with diagnosed diabetes (type 1 or type 2 diabetes), however, 11.7 million Canadians are living with diabetes or prediabetes, a condition that, if left unmanaged, can develop into type 2 diabetes. Diabetes is also costing the healthcare system USD 30 billion per year to treat people with diabetes. The high prevalence of diabetes and its overwhelming impact on Canadian communities and the healthcare system means that we must further diabetes research.

Diabetes Canada and the Canadian Pharmacists Association (CPhA) are actively monitoring coronavirus issues, in collaboration with the Canadian local government and diabetes devices manufacturers, to remain available for all Canadians, and stated that “based on the information from device manufacturers, there have been no COVID-19 related shortages reported in Canada”.

As a result, Canada's diabetes devices market is predicted to expand gradually in the coming years.

Canada Diabetes Care Devices Market: Diabetes Population in million, (2016-2021)

Canada Diabetes Care Devices Market Competitor Analysis

The new technologies in diabetes devices, like continuous glucose monitoring, increased the market for monitoring devices. The mergers and acquisitions between the players, like the acquisition of TypeZero Technologies by Dexcom, are paving the way for automated insulin delivery. The acquisition has sent Dexcom ahead on its way in the race to create an artificial pancreas system, rather than merely offering a boost to the continuous glucose monitoring devices market.

Canada Diabetes Care Devices Market Top Players

  1. Dexcom

  2. Medtronic

  3. Novo Nordisk A/S

  4. F. Hoffmann-La Roche AG

  5. Abbott Diabetes Care

*Disclaimer: Major Players sorted in no particular order

Canada Diabetes Devices Market Concentration

Canada Diabetes Care Devices Market Recent Developments

In March 2022, the Ontario government announced it will provide coverage for the Dexcom G6 CGM System through Ontario’s Assistive Devices Program (ADP) for people in the province living with type 1 diabetes who are over 2 years of age and meet coverage criteria. Ontario joins six other provinces or territories, most recently Alberta, offering public coverage of CGM systems under provincial health plans. The Non-Insured Health Benefits Program also provides coverage for First Nations and Inuit children. With expanded public coverage for CGM, more people can access this standard of care technology, helping them to manage a life-long chronic illness more effectively.

In July 2022, NuGen Medical Devices Inc. announced that its needle-free injection system and accessories, also known as InsuJet, have been approved by Health Canada specifically for the needle-free delivery of insulin. While NuGen previously announced on December 9, 2021, that its needle-free injection system had received general use approval from Health Canada, the insulin-specific approval is the first ever insulin-specific needle-free system approved by Health Canada to sell into the healthcare system and its end users. Additionally, this approval may also aid in the process of obtaining coverage for the system by certain health care insurance providers in Canada.

Canada Diabetes Care Devices Market Report - Table of Contents


    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Dynamics

      1. 4.2.1 Market Drivers

      2. 4.2.2 Market Restraints

    3. 4.3 Industry Attractiveness - Porter's Five Forces Analysis

      1. 4.3.1 Bargaining Power of Suppliers

      2. 4.3.2 Bargaining Power of Consumers

      3. 4.3.3 Threat of New Entrants

      4. 4.3.4 Threat of Substitute Products and Services

      5. 4.3.5 Intensity of Competitive Rivalry

  5. 5. Market Segmentation

    1. 5.1 By Device

      1. 5.1.1 By Monitoring Devices, (Value and Volume, 2016 - 2027)

        1. Self-monitoring Blood Glucose Devices

          1. Glucometer Devices

          2. Test Strips

          3. Lancets

        2. Continuous Glucose Monitoring

          1. Sensors

          2. Receivers (Receivers and Transmitters)

      2. 5.1.2 By Management Devices, (Value and Volume, 2016 - 2027)

        1. Insulin Delivery Devices

          1. Insulin Pump

            1. Insulin Pump Device

            2. Insulin Pump Reservoir

            3. Infusion Set

          2. Insulin Syringes

          3. Insulin Disposable Pens

          4. Insulin Cartridges in Reusable pens

          5. Insulin Jet Injectors


    1. 6.1 Type 1 Diabetes Population (2016 - 2027)

    2. 6.2 Type 2 Diabetes Population (2016 - 2027)



      1. 7.1.1 Novo Nordisk A/S

      2. 7.1.2 Sanofi Aventis

      3. 7.1.3 Eli Lilly

      4. 7.1.4 F. Hoffmann-La Roche Ltd

      5. 7.1.5 Abbott Diabetes Care

      6. 7.1.6 Johnson and Johnson (Lifescan)

      7. 7.1.7 Arkray

      8. 7.1.8 Ascensia Diabetes Care

      9. 7.1.9 AgaMatrix Inc.

      10. 7.1.10 Dexcom

      11. 7.1.11 Medtronic

      12. 7.1.12 Ypsomed Holding AG

      13. 7.1.13 Terumo

      14. 7.1.14 LMC Diabetes and Endocrinology

      15. 7.1.15 Bayshore Health Care

      16. 7.1.16 Express Scripts

      17. 7.1.17 One Drop

      18. 7.1.18 TELUS Health


You can also purchase parts of this report. Do you want to check out a section wise price list?

Canada Diabetes Care Devices Market Research FAQs

The Canada Diabetes Care Devices Market is studied from 2018 - 2028.

The Canada Diabetes Care Devices Market is growing at a CAGR of >6% over the next 5 years.

The Canada Diabetes Care Devices Market is valued at 1 Billion USD in 2018.

The Canada Diabetes Care Devices Market is valued at 2 Billion USD in 2028.

Dexcom, Medtronic, Novo Nordisk A/S, F. Hoffmann-La Roche AG, Abbott Diabetes Care are the major companies operating in Canada Diabetes Care Devices Market.

Canada Diabetes Care Devices Industry Reports

In-depth industry statistics and market share insights of the Canada Diabetes Care Devices sector for 2020, 2021, and 2022. The Canada Diabetes Care Devices research report provides a comprehensive outlook of the market size and an industry growth forecast for 2023 to 2028. Available to download is a free sample file of the Canada Diabetes Care Devices report PDF.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!